Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 6746870, 12 pages
https://doi.org/10.1155/2017/6746870
Review Article

TWEAK/Fn14 Activation Participates in Skin Inflammation

Department of Dermatology, The Second Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, China

Correspondence should be addressed to Yumin Xia; moc.361@2021nimuyaix

Received 18 May 2017; Accepted 1 August 2017; Published 6 September 2017

Academic Editor: Juarez A. S. Quaresma

Copyright © 2017 Qilu Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Chicheportiche, P. R. Bourdon, H. Xu et al., “TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis,” The Journal of Biological Chemistry, vol. 19, no. 272, pp. 32401–32410, 1997. View at Google Scholar
  2. J. A. Winkles, “The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting,” Nature Reviews Drug Discovery, vol. 7, no. 5, pp. 411–425, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. A. Brown, C. M. Richards, H. N. Hanscom, S. L. Feng, and J. A. Winkles, “The Fn14 cytoplasmic tail binds tumor necrosis factor receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation,” Biochemical Journal, vol. 371, Part 2, pp. 395–403, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Maecker, E. Varfolomeev, F. Kischkel et al., “TWEAK attenuates the transition from innate to adaptive immunity,” Cell, vol. 123, no. 5, pp. 931–944, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. T. G. Bird, W. Y. Lu, L. Boulter et al., “Bone marrow injection stimulates hepatic ductular reactions in the absence of injury via macrophage-mediated TWEAK signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 16, pp. 6542–6547, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Madrigal-Matute, V. Fernandez-Laso, C. Sastre et al., “TWEAK/Fn14 interaction promotes oxidative stress through NADPH oxidase activation in macrophages,” Cardiovascular Research, vol. 108, no. 1, pp. 139–147, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. M. N. Sharif, G. Campanholle, E. E. Nagiec et al., “Soluble Fn14 is detected and elevated in mouse and human kidney disease,” PLoS One, vol. 11, no. 5, article e0155368, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Liu, L. Peng, L. Li et al., “TWEAK/Fn14 activation contributes to the pathogenesis of bullous pemphigoid,” Journal of Investigative Dermatology, vol. 137, no. 7, pp. 1512–1522, 2017. View at Publisher · View at Google Scholar
  9. L. Gu, L. Dai, C. Cao et al., “Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention,” PLoS One, vol. 8, no. 3, article e57436, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. C. L. Armstrong, R. Galisteo, S. A. Brown, and J. A. Winkles, “TWEAK activation of the non-canonical NF-κB signaling pathway differentially regulates melanoma and prostate cancer cell invasion,” Oncotarget, vol. 7, no. 49, pp. 81474–81492, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. B. R. Lin, M. T. Huang, S. T. Chen et al., “Prognostic significance of TWEAK expression in colorectal cancer and effect of its inhibition on invasion,” Annals of Surgical Oncology, vol. 19, Supplement 3, pp. S385–S394, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. J. G. Perez, N. L. Tran, M. G. Rosenblum et al., “The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics,” Oncogene, vol. 35, no. 17, pp. 2145–2155, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Wajant, “The TWEAK-Fn14 system as a potential drug target,” British Journal of Pharmacology, vol. 170, no. 4, pp. 748–764, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. J. L. Doerner, J. Wen, Y. Xia et al., “TWEAK/Fn14 signaling involvement in the pathogenesis of cutaneous disease in the MRL/lpr model of spontaneous lupus,” Journal of Investigative Dermatology, vol. 135, no. 8, pp. 1986–1995, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. M. M. Tajrishi, S. Sato, J. Shin, T. S. Zheng, L. C. Burkly, and A. Kumar, “The TWEAK-Fn14 dyad is involved in age-associated pathological changes in skeletal muscle,” Biochemical and Biophysical Research Communications, vol. 446, no. 4, pp. 1219–1224, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Wen, J. Doerner, K. Weidenheim et al., “TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice,” Journal of Autoimmunity, vol. 60, no. 1, pp. 40–50, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Chen, L. Wei, and Y. Xia, “Roles of tumour necrosis factor-related weak inducer of apoptosis/fibroblast growth factor-inducible 14 pathway in lupus nephritis,” Nephrology (Carlton), vol. 22, no. 2, pp. 101–106, 2017. View at Publisher · View at Google Scholar
  18. J. M. Weinberg, “TWEAK-Fn14 as a mediator of acute kidney injury,” Kidney International, vol. 79, no. 2, pp. 151–153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. L. C. Burkly, “TWEAK/Fn14 axis: the current paradigm of tissue injury-inducible function in the midst of complexities,” Seminars in Immunology, vol. 26, no. 3, pp. 229–236, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Novoyatleva, A. Sajjad, and F. B. Engel, “TWEAK-Fn14 cytokine-receptor axis: a new player of myocardial remodeling and cardiac failure,” Frontiers in Immunology, vol. 5, p. 50, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. L. C. Burkly, J. S. Michaelson, and T. S. Zheng, “TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses,” Immunological Reviews, vol. 244, no. 1, pp. 99–114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Cheng, M. Xu, X. Liu, X. Zou, N. Zhan, and Y. Xia, “TWEAK/Fn14 activation induces keratinocyte proliferation under psoriatic inflammation,” Experimental Dermatology, vol. 25, no. 1, pp. 32–37, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Wilhelm, E. L. Shepherd, A. Amatucci et al., “Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation,” The Journal of Pathology, vol. 239, no. 1, pp. 109–121, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Peternel, T. Manestar-Blažić, I. Brajac, L. Prpić-Massari, and M. Kaštelan, “Expression of TWEAK in normal human skin, dermatitis and epidermal neoplasms: association with proliferation and differentiation of keratinocytes,” Journal of Cutaneous Pathology, vol. 38, no. 10, pp. 780–789, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. H. D. Dhruv, T. G. Whitsett, N. M. Jameson et al., “Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation,” Carcinogenesis, vol. 35, no. 1, pp. 218–226, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Martínez-Aranda, V. Hernández, E. Guney et al., “FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies,” Oncotarget, vol. 6, no. 42, pp. 44254–44273, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Xu, F. Zhang, A. Wang et al., “Tumor necrosis factor-like weak inducer of apoptosis promotes hepatic stellate cells migration via canonical NF-κB/MMP9 pathway,” PLoS One, vol. 11, no. 12, article e0167658, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Zimmermann, A. Koreck, N. Meyer et al., “TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosis,” Journal of Allergy & Clinical Immunology, vol. 127, no. 1, pp. 200–207, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Ameri, H. Liu, R. Liu et al., “TWEAK/Fn14 pathway is a novel mediator of retinal neovascularization,” Investigative Ophthalmology & Visual Science, vol. 55, no. 2, pp. 801–813, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. L. D. Martino, M. Dave, P. Menghini et al., “Protective role for TWEAK/Fn14 in regulating acute intestinal inflammation and colitis-associated tumorigenesis,” Cancer Research, vol. 76, no. 22, pp. 6533–6542, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. M. A. Fung and K. L. Barr, “Current knowledge in inflammatory dermatopathology,” Dermatologic Clinics, vol. 30, no. 4, pp. 667–684, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. I. M. Michalek, B. Loring, and S. M. John, “A systematic review of worldwide epidemiology of psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 31, no. 2, pp. 205–212, 2017. View at Publisher · View at Google Scholar · View at Scopus
  33. I. A. Deckers, S. McLean, S. Linssen, M. Mommers, C. P. van Schayck, and A. Sheikh, “Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies,” PLoS One, vol. 7, no. 7, article e39803, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Pina, R. Blanco, and M. A. González-Gay, “Cutaneous vasculitis: a rheumatologist perspective,” Current Allergy and Asthma Reports, vol. 13, no. 5, pp. 545–554, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Jarukitsopa, D. D. Hoganson, and C. S. Crowson, “Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States,” Arthritis Care & Research, vol. 67, no. 6, pp. 817–828, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Smola, “Human papillomaviruses and skin cancer,” Advances in Experimental Medicine and Biology, vol. 810, no. 5, pp. 192–207, 2014. View at Google Scholar
  37. S. Bedoui and M. Greyer, “The role of dendritic cells in immunity against primary herpes simplex virus infections,” Frontiers in Microbiology, vol. 5, p. 533, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Xia, L. C. Herlitz, S. Gindea et al., “Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis,” Journal of the American Society of Nephrology, vol. 26, no. 5, pp. 1053–1070, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Wen, Y. Xia, A. Stock et al., “Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway,” Journal of Autoimmunity, vol. 43, pp. 44–54, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Xia, S. R. Campbell, A. Broder et al., “Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis,” Clinical Immunology, vol. 145, no. 2, pp. 108–121, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. A. D. Stock, J. Wen, and C. Putterman, “Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway,” Frontier of Immunology, vol. 4, p. 484, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. W. H. Boehncke and M. P. Schön, “Psoriasis,” Lancet, vol. 386, no. 9997, pp. 983–994, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. M. J. Bou-Dargham, Z. Khamis, A. B. Cognetta, and Q. A. Sang, “The role of interleukin-1 in inflammatory and malignant human skin diseases and the rationale for targeting interleukin-1 alpha,” Medicinal Research Reviews, vol. 37, no. 1, pp. 180–216, 2017. View at Publisher · View at Google Scholar
  44. C. Roos, A. Wicovsky, N. Müller et al., “Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway,” Journal of Immunology, vol. 185, no. 3, pp. 1593–1695, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Pellegrini, L. Willen, M. Perroud et al., “Structure of the extracellular domains of human and Xenopus Fn14: implications in the evolution of TWEAK and Fn14 interactions,” The FEBS Journal, vol. 280, no. 8, pp. 1818–1829, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Dhruv, J. C. Loftus, P. Narang et al., “Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis,” The Journal of Biological Chemistry, vol. 288, no. 45, pp. 32261–32276, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. S. A. Brown, H. N. Hanscom, H. Vu, S. A. Brew, and J. A. Winkles, “TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules,” The Journal of Biological Chemistry, vol. 397, no. 2, pp. 297–304, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Gröne, “Keratinocytes and cytokines,” Veterinary Immunology and Immunopathology, vol. 88, no. 1-2, pp. 1–12, 2008. View at Google Scholar
  49. M. J. Carr, Y. Li, A. M. Rezakhanlou, and A. Ghahary, “Keratinocyte-releasable factors stimulate the expression of granulocyte colony-stimulating factor in human dermal fibroblasts,” Journal of Cellular Biochemistry, vol. 118, no. 2, pp. 308–317, 2017. View at Publisher · View at Google Scholar
  50. A. Gragnani, M. V. Cezillo, I. D. da Silva, S. M. de Noronha, S. A. Correa-Noronha, and L. M. Ferreira, “Gene expression profile of cytokines and receptors of inflammation from cultured keratinocytes of burned patients,” Burns, vol. 40, no. 5, pp. 947–956, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Ondet, B. Muscatelli-Groux, C. Coulouarn et al., “The release of pro-inflammatory cytokines is mediated via MAP-kinases rather than inflammasome signaling pathway in keratinocytes,” Clinical and Experimental Pharmacology and Physiology, vol. 44, no. 7, pp. 827–838, 2017. View at Publisher · View at Google Scholar
  52. M. Niebuhr, K. Baumert, and T. Werfel, “TLR-2-mediated cytokine and chemokine secretion in human keratinocytes,” Experimental Dermatology, vol. 19, no. 10, pp. 873–877, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Kondo, “The roles of keratinocyte-derived cytokines in the epidermis and their possible responses to UVA-irradiation,” Journal of Investigative Dermatology Symposium Proceedings, vol. 4, no. 2, pp. 177–183, 1999. View at Google Scholar
  54. J. H. Peters, G. S. Tjabringa, E. Fasse et al., “Co-culture of healthy human keratinocytes and T-cells promotes keratinocyte chemokine production and RORγt-positive IL-17 producing T-cell populations,” Journal of Dermatological Science, vol. 69, no. 1, pp. 44–53, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. E. G. Harper, C. Guo, H. Rizzo et al., “Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis,” Journal of Investigative Dermatology, vol. 129, no. 9, pp. 2175–2183, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Karthikeyan, G. Kanimozhi, N. R. Prasad et al., “7-Hydroxycoumarin prevents UVB-induced activation of NF-κB and subsequent overexpression of matrix metalloproteinases and inflammatory markers in human dermal fibroblast cells,” Journal of Photochemistry and Photobiology B: Biology, vol. 161, pp. 170–176, 2016. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Wong, J. A. McGrath, and H. Navsaria, “The role of fibroblasts in tissue engineering and regeneration,” British Journal of Dermatology, vol. 156, no. 6, pp. 1149–1155, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. M. A. Seeger and A. S. Paller, “The roles of growth factors in keratinocyte migration,” Advanced Wound Care (New Rochelle), vol. 4, no. 4, pp. 213–224, 2015. View at Publisher · View at Google Scholar
  59. S. Werner and H. Smola, “Paracrine regulation of keratinocyte proliferation and differentiation,” Trends in Cell Biology, vol. 11, no. 4, pp. 143–146, 2001. View at Google Scholar
  60. A. S. Yazdi, M. Röcken, and K. Ghoreschi, “Cutaneous immunology: basics and new concepts,” Seminars in Immunopathology, vol. 38, no. 1, pp. 3–10, 2016. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Castiglioni, A. Cazzaniga, and J. A. Maier, “Potential interplay between NF-κB and PPARγ in human dermal microvascular endothelial cells cultured in low magnesium,” Magnesium Research Official Organ of the International Society for the Development of Research on Magnesium, vol. 27, no. 2, pp. 86–93, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. L. C. Burkly, J. S. Michaelson, K. Hahm, A. Jakubowski, and T. S. Zheng, “TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease,” Cytokine, vol. 40, no. 1, pp. 1–16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. L. Jin, A. Nakao, M. Nakayama et al., “Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes,” Journal of Investigative Dermatology, vol. 122, no. 5, pp. 1175–1179, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Cheng, N. Zhan, D. Ding et al., “HPV type 16 infection switches keratinocytes from apoptotic to proliferative fate under TWEAK/Fn14 interaction,” Journal of Investigative Dermatology, vol. 135, no. 10, pp. 2427–2436, 2015. View at Publisher · View at Google Scholar · View at Scopus
  65. D. Sidler, P. Wu, R. Herro et al., “TWEAK mediates inflammation in experimental atopic dermatitis and psoriasis,” Nature Communications, vol. 8, article 15395, 2017. View at Publisher · View at Google Scholar
  66. Y. Chicheportiche, R. Chicheportiche, I. Sizing et al., “Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies,” Arthritis Research & Therapy, vol. 4, no. 2, pp. 126–133, 2001. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Chen, J. Liu, M. Yang et al., “Fn14, a downstream target of the TGF-β signaling pathway, regulates fibroblast activation,” PLoS One, vol. 10, no. 12, article e0143802, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. A. B. Sanz, L. S. Aroeira, T. Bellon et al., “TWEAK promotes peritoneal inflammation,” PLoS One, vol. 9, no. 3, article e90399, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. A. W. van Kuijk, C. A. Wijbrandts, M. Vinkenoog, T. S. Zheng, K. A. Reedquist, and P. P. Tak, “TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade,” Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 301–304, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Liu, M. Xu, X. Min et al., “TWEAK/Fn14 activation participates in Ro52-mediated photosensitization in cutaneous lupus erythematosus,” Frontiers in Immunology, vol. 8, p. 651, 2017. View at Publisher · View at Google Scholar
  71. T. Chen, Z. P. Guo, L. Li et al., “Tumor necrosis factor-like weak inducer of apoptosis enhances E-selectin and ICAM-1 expression, and may contribute to the development of cutaneous vasculitis,” PLoS One, vol. 8, no. 2, article e56830, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. P. J. Naudé, J. A. den Boer, P. G. Luiten, and U. L. Eisel, “Tumor necrosis factor receptor cross-talk,” The FEBS Journal, vol. 278, no. 6, pp. 888–898, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. L. Puimège, C. Libert, and F. V. Hauwermeiren, “Regulation and dysregulation of tumor necrosis factor receptor-1,” Cytokine & Growth Factor Reviews, vol. 25, no. 3, pp. 285–300, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Youn, H. Y. Kim, J. H. Park et al., “Regulation of TNF-alpha-mediated hyperplasia through TNF receptors, TRAFs, and NF-kappaB in synoviocytes obtained from patients with rheumatoid arthritis,” Immunology Letters, vol. 83, no. 2, pp. 85–93, 2002. View at Google Scholar
  75. M. Rothe, S. C. Wong, W. J. Henzel, and D. V. Goeddel, “A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor,” Cell, vol. 78, no. 4, pp. 681–692, 1994. View at Publisher · View at Google Scholar · View at Scopus
  76. B. Favaloro, N. Allocati, V. Graziano, C. Di Ilio, and V. De Laurenzi, “Role of apoptosis in disease,” Aging (Albany NY), vol. 4, no. 5, pp. 330–349, 2012. View at Publisher · View at Google Scholar
  77. D. Brenner, H. Blaser, and T. W. Mak, “Regulation of tumour necrosis factor signalling: live or let die,” Nature Reviews Immunology, vol. 15, no. 6, pp. 362–374, 2015. View at Publisher · View at Google Scholar · View at Scopus
  78. D. Faustman and M. Davis, “TNF receptor 2 pathway: drug target for autoimmune diseases,” Nature Reviews Drug Discovery, vol. 9, no. 6, pp. 482–493, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. D. Vucic, “The role of ubiquitination in TWEAK-stimulated signaling,” The Frontier of Immunology, vol. 4, p. 472, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. K. K. Hong, M. J. Gwak, J. Song, and N. I. Kim, “Nuclear factor-κB pathway activation and phosphatase and tensin homolog downregulation in psoriasis,” British Journal of Dermatology, vol. 174, no. 2, pp. 433–435, 2016. View at Publisher · View at Google Scholar · View at Scopus
  81. X. Liu, Y. Liu, M. Xu et al., “Zinc finger protein A20 is involved in the antipsoriatic effect of calcipotriol,” British Journal of Dermatology, vol. 175, no. 2, pp. 314–324, 2016. View at Publisher · View at Google Scholar · View at Scopus
  82. A. M. Goldminz, S. C. Au, and N. Kim, “NF-κB: an essential transcription factor in psoriasis,” Journal of Dermatological Science, vol. 69, no. 2, pp. 89–94, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Yan, Z. Xu, F. Lou et al., “NF-κB-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis,” Nature Communications, vol. 6, p. 7652, 2015. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Szegedi, R. Lutter, P. C. Res et al., “Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin,” Journal of the European Academy of Dermatology and Venereology, vol. 29, no. 11, pp. 2136–2144, 2015. View at Publisher · View at Google Scholar · View at Scopus
  85. Ö. Bilgiç, A. Sivrikaya, A. Toker, A. Ünlü, and C. Altınyazar, “Serum levels of TWEAK in patients with psoriasis vulgaris,” Cytokine, vol. 77, pp. 10–13, 2016. View at Publisher · View at Google Scholar · View at Scopus
  86. T. Chen, W. D. Xu, Y. Zhao, and Y. Liu, “Role of the TWEAK/Fn14 pathway in autoimmune diseases,” Immunologic Research, vol. 64, no. 1, pp. 44–50, 2016. View at Publisher · View at Google Scholar · View at Scopus
  87. Y. Chen, E. S. Lind, C. Johansson et al., “The expression of BAFF, APRIL and TWEAK is altered in eczema skin but not in the circulation of atopic and seborrheic eczema patients,” PLoS One, vol. 6, no. 7, article e22202, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. F. He, W. Dang, K. Saito et al., “Solution structure of the cysteine-rich domain in Fn14, a member of the tumor necrosis factor receptor superfamily,” Protein Science, vol. 18, no. 3, pp. 650–656, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. S. S. Alaou, V. Dessirier, E. D. Araujo et al., “TWEAK affects keratinocyte G2/M growth arrest and induces apoptosis through the translocation of the AIF protein to the nucleus,” PLoS One, vol. 7, no. 3, article e33609, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. J. E. Vince, D. Chau, B. Callus et al., “TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNF-alpha,” Journal of Cell Biology, vol. 182, no. 1, pp. 171–184, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Li, T. Chen, Z. Guo, J. Li, and N. Cao, “Tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 are expressed in urticarial vasculitis,” Journal of Dermatology, vol. 40, no. 11, pp. 891–895, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. T. Chen, Z. P. Guo, M. M. Li et al., “Tumor necrosis factor like weak inducer of apoptosis (TWEAK), an important mediator of endothelial inflammation, is associated with the pathogenesis of Henoch-Schonlein purpura,” Clinical & Experimental Immunology, vol. 166, no. 1, pp. 64–71, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. P. J. Donohue, C. M. Richards, S. A. Brown et al., “TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 4, pp. 594–600, 2003. View at Publisher · View at Google Scholar · View at Scopus
  94. N. Harada, M. Nakayama, H. Nakano, Y. Fukuchi, H. Yagita, and K. Okumura, “Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells,” Biochemical and Biophysical Research Communications, vol. 299, no. 3, pp. 488–493, 2002. View at Google Scholar
  95. D. Stephan, O. Sbai, and J. Wen, “TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier,” Journal of Neuroinflammation, vol. 10, p. 9, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. C. H. Yuan, M. Filippova, S. S. Tungteakkhun, P. J. Duerksen-Hughes, and J. L. Krstenansky, “Small molecule inhibitors of the HPV16-E6 interaction with caspase 8,” Bioorganic & Medicinal Chemistry Letters, vol. 22, no. 5, pp. 2125–2129, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. J. Manzo-Merino, P. Massimi, M. Lizano, and L. Banks, “The human papillomavirus (HPV) E6 oncoproteins promotes nuclear localization of active caspase 8,” Virology, vol. 450-451, no. 1, pp. 146–152, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. C. Chelimo, T. A. Wouldes, L. D. Cameron, and J. M. Elwood, “Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer,” Journal of Infection, vol. 66, no. 3, pp. 207–217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. B. Aldabagh, J. G. Angeles, A. R. Cardones, and S. T. Arron, “Cutaneous squamous cell carcinoma and human papillomavirus: is there an association?” Dermatological Surgery, vol. 39, Part 1, no. 1, pp. 1–23, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. R. Yoriki, S. Akashi, M. Sho et al., “Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer,” Experimental & Therapeutic Medicine, vol. 2, no. 1, pp. 103–108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. G. S. Watts, N. L. Tran, M. E. Berens et al., “Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma,” International Journal of Cancer, vol. 121, no. 3, pp. 2132–2139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. X. Terra, D. Gómez, J. García-Lorenzo et al., “External validation of sTWEAK as a prognostic noninvasive biomarker for head and neck squamous cell carcinoma,” Head & Neck, vol. 38, Suppement 1, pp. E1358–E1363, 2016. View at Publisher · View at Google Scholar · View at Scopus
  103. T. S. Zheng and L. C. Burkly, “No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies,” Journal of Leukocyte Biology, vol. 84, no. 2, pp. 338–347, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. Z. Zhao, L. C. Burkly, S. Campbell et al., “TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus,” Journal of Immunology, vol. 179, no. 11, pp. 7949–7958, 2001. View at Publisher · View at Google Scholar
  105. S. Desplat-Jégo, R. Creidy, S. Varriale et al., “Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis,” Clinical Immunology, vol. 117, no. 1, pp. 15–23, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. J. Y. Choe and S. K. Kim, “Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus,” Inflammation Research, vol. 65, no. 6, pp. 479–488, 2016. View at Publisher · View at Google Scholar · View at Scopus
  107. Q. L. Peng, X. M. Shu, X. L. Tian, X. Lu, and G. C. Wang, “Expression of tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 in patients with polymyositis and dermatomyositis,” Arthritis Research & Therapy, vol. 16, no. 1, article R16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  108. N. Mikita, T. Ikeda, M. Ishiguro, and F. Furukawa, “Recent advances in cytokines in cutaneous and systemic lupus erythematosus,” Journal of Dermatology, vol. 38, no. 9, pp. 839–849, 2011. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Doerner, S. A. Chalmers, A. Friedman, and C. Putterman, “Fn14 deficiency protects lupus-prone mice from histological lupus erythematosus-like skin inflammation induced by ultraviolet light,” Experimental Dermatology, vol. 25, no. 12, pp. 969–976, 2016. View at Publisher · View at Google Scholar · View at Scopus
  110. L. C. Bover, M. Cardó-Vila, A. Kuniyasu et al., “A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications,” Journal of Immunology, vol. 178, no. 12, pp. 8183–8194, 2007. View at Google Scholar
  111. O. Kowal-Bielecka, M. Bielecki, S. Guiducci et al., “High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis,” Arthritis Research & Therapy, vol. 15, no. 3, article R69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. G. Hu, W. Zeng, and Y. Xia, “TWEAK/Fn14 signaling in tumors,” Tumor Biology, vol. 39, no. 6, article 1010428317714624, 2017. View at Publisher · View at Google Scholar
  113. E. S. Fortin, I. T. Mathews, J. M. Eschbacher, J. C. Loftus, M. H. Symons, and N. L. Tran, “The Src homology 3 domain-containing guanine nucleotide exchange factor is overexpressed in high-grade gliomas and promotes tumor necrosis factor-like weak inducer of apoptosis-fibroblast growth factor-inducible 14-induced cell migration and invasion via tumor necrosis factor receptor-associated factor 2,” The Journal of Biological Chemistry, vol. 288, no. 30, pp. 21887–21897, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. K. Yanaba, A. Yoshizaki, E. Muroi et al., “Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis,” The Journal of Rheumatology, vol. 36, no. 8, pp. 1657–1662, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Sato, Y. Ogura, and A. Kumar, “TWEAK/Fn14 signaling axis mediates skeletal muscle atrophy and metabolic dysfunction,” Frontiers in Immunology, vol. 5, p. 18, 2014. View at Publisher · View at Google Scholar · View at Scopus
  116. S. Bhatnagar, A. Mittal, S. K. Gupta, and A. Kumar, “TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases,” Journal of Cellular Physiology, vol. 227, no. 3, pp. 1042–1051, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. J. S. Park, S. M. Kim, K. A. Jung et al., “Inhibition of the TWEAK/Fn14 pathway attenuates autoimmune arthritis in a SKG mouse model,” Histology and Histopathology, vol. 32, no. 5, pp. 481–490, 2017. View at Publisher · View at Google Scholar
  118. T. Chen, Z. P. Guo, L. X. Fu, N. Cao, and S. Qin, “Anti-TWEAK monoclonal antibodies reduce vascular damage and leucocyte infiltration in a mouse model of cutaneous reverse passive Arthus reaction,” Clinical and Experimental Dermatology, vol. 41, no. 8, pp. 871–877, 2016. View at Publisher · View at Google Scholar · View at Scopus
  119. N. Wisniacki, L. Amaravadi, G. R. Galluppi et al., “Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis,” Clinical Therapeutics, vol. 35, no. 8, pp. 1137–1149, 2013. View at Publisher · View at Google Scholar · View at Scopus
  120. R. S. Yadava, E. P. Foff, Q. Yu et al., “TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy,” Human Molecular Genetics, vol. 24, no. 7, pp. 2035–2048, 2015. View at Publisher · View at Google Scholar · View at Scopus
  121. X. Yin, L. Luistro, H. Zhong et al., “RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response,” Clinical Cancer Research, vol. 19, no. 20, pp. 5685–5698, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. U. Lassen, J. H. M. Schellens, L. L. Siu et al., “A first-in-human phase I monotherapy study of RG7212 (R), a novel monoclonal antibody targeting TWEAK signaling in patients with advanced solid tumors,” European Journal of Cancer, vol. 48, no. 12, pp. 71828–71832, 2012. View at Publisher · View at Google Scholar
  123. H. Prinzhadad, T. Mizrachi, M. Irony-Tur-Sinai et al., “Amelioration of autoimmune neuroinflammation by the fusion molecule Fn14·TRAIL,” Journal of Neuroinflammation, vol. 10, p. 36, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. S. Salzmann, A. Seher, and J. Trebing, “Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity,” Journal of Biological Chemistry, vol. 288, no. 19, pp. 13455–13466, 2013. View at Publisher · View at Google Scholar · View at Scopus